ResearcherChina Pharmaceutical UniversityActive in the last 2 years
Jiayu Ding
Matched on ORCID iD 0000-0001-9264-218X; OpenAlex author ID A5029288176. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper
Papers 3
- ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling Pathway. Co-author DOI 10.1002/advs.202506718↗
- PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis. Co-author DOI 10.3389/fimmu.2022.805311↗
- Systematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14153629↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wenbin Kuang · 3 shared papers, 2022–2025 · strength 0.51
- Paper ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PA… DOI 10.1002/advs.202506718↗
- Paper PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and … DOI 10.3389/fimmu.2022.805311↗
- Paper Systematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma. DOI 10.3390/cancers14153629↗
- Xiao Wang · 3 shared papers, 2022–2025 · strength 0.51
- Paper ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PA… DOI 10.1002/advs.202506718↗
- Paper PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and … DOI 10.3389/fimmu.2022.805311↗
- Paper Systematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma. DOI 10.3390/cancers14153629↗
- Peng Yang · 3 shared papers, 2022–2025 · strength 0.51
- Paper ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PA… DOI 10.1002/advs.202506718↗
- Paper PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and … DOI 10.3389/fimmu.2022.805311↗
- Paper Systematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma. DOI 10.3390/cancers14153629↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.